Medtech In Politics: A Look At Republican And Democratic Party Platforms
Executive Summary
The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.
You may also be interested in...
2018 Global Approvals Analysis: Emerging-Market Regulators And Companies Make Their Presence Felt
The list of medical device approvals outside the US captured by Medtech Insight's Approvals Tracker in 2018 was shorter than in 2017, but it includes approvals from 14 different territories – more than one-fifth of the approvals came from emerging markets – covering more than 50 different indication categories.
The Trump Conundrum: Republicans Will Run US Government, But Incoming President Is A Wildcard
An underlying question is how well a President Trump will work with lawmakers in his own party, many of whom did not see eye to eye with the candidate at the top of their ticket during the campaign. There is also more uncertainty than usual about anticipated cabinet and agency appointments, such as for FDA and CMS, under the Trump administration.
Industry Gives Big Money To GOP Senators Backing Device Reforms, But Buys Into Clinton Over Trump, 14-1
In the 2016 election race, the most generous device and diagnostic industry contributors donated heavily to Senate Republicans giving legislative attention to FDA regulatory reforms – Richard Burr, N.C., Kelly Ayotte, N.H., Pat Toomey, Pa. – running close races against Democrat challengers. But while industry primarily backs GOP senators, they also favor Hillary Clinton (D) over Donald Trump (R) with their donations, 14-1.